Not provided
Not provided
Not provided
Not provided
Emergency Use Authorizations for monoclonal antibodies withdrawn
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Pittsburgh | OTHER |
Not provided
Not provided
Not provided
Multiple monoclonal antibodies (mABs) have been shown to reduce viral burden and improve clinical outcomes, have been granted FDA Emergency Use Authorization (EUA) for use in select populations, and are routinely used in the UPMC Health System, which has made expanded access a priority. However, the comparative effectiveness of these mABS is unknown. The National Academies of Sciences, Engineering, and Medicine has called for expanded access and clinical use of mABs, noting it is "critical to collect data and evaluate whether they are working as predicted". This pragmatic evaluation will determine the relative effects of the EUA-governed mABs versus each other. When U.S. government mAB policies change (e.g., FDA grants or revokes EUAs), UPMC Health System policies and the evaluated mABs will accordingly change.
While COVID-19 vaccination will reduce COVID-19-related morbidity and mortality, the learned immune response may vary between individuals. This means interventions such as monoclonal antibodies (mAB) will still be needed to prevent progression of COVID-19 illness. Monoclonal antibodies seek to mimic or enhance the natural immune system response against a pathogen and are often used in the care of patients with cancer or infection.
For viral infections, mABs are created by exposing a white blood cell to a particular viral protein, which is then cloned to mass produce antibodies to target that virus. For SARS-CoV-2, the virus that causes COVID-19, IgG1 mABs target the spike protein of SARS-CoV-2 and block viral attachment and entry into cells.
The SARS-CoV-2 mABs bamlanivimab and etesevimab, and the REGN-COV2 combination (casirivimab + imdevimab) reduce nasopharyngeal viral burden plus clinical outcomes including future emergency department visits and hospitalizations. Each received FDA Emergency Use Authorization (EUA) for use in selected populations.
As of February 2021, there are over 60,000 new cases of COVID-19 diagnosed daily in the US, with over 7000 daily COVID-19 related hospital admissions. Although case volumes are currently declining, COVID-19 remains a significant public health threat.
Despite the EUAs, the clinical use of mABs is low due in part to lack of patient access, complexities in drug allocation, and lack of knowledge among providers are contributing factors. Further, the comparative effectiveness of different mABs is unknown and not yet directly studied. The National Academies of Sciences, Engineering, and Medicine recently called for expanded access and clinical use of mABs, noting it is "critical to collect data and evaluate whether they are working as predicted". This evaluation seeks to determine their relative effects versus each other, starting with those governed by EUAs.
OPTIMISE-C19 is a quality improvement (QI) study, governed by approvals from both the UPMC QI committee and the University of Pittsburgh IRB. Currently, mAB therapy is approved for use under EUA issued by the FDA. There are no data on the relative benefits of one mAB versus any other. mABs are ordered by UPMC physicians as a generic referral order and the order is filled by UPMC pharmacy via therapeutic interchange. The selection of mABs available within pharmacy is overseen by the UPMC pharmacy and therapeutics committee. OPTIMISE-C19 provides the therapeutic interchange via random allocation. The UPMC Quality Improvement Committee approved the OPTIMISE-C19 study, including the random therapeutic interchange. The University of Pittsburgh IRB considered the randomized therapeutic interchange to be quality improvement and approved the additional data collection and analyses.
Patients provide verbal consent to receive mAB therapy. UPMC requires physicians to provide and review with patients the EUA Fact Sheet for each mAB, and explain that the patient could receive any of the EUA-governed mABs. As per EUA requirements, physicians discuss the risks and benefits of mABs with patients, and patients consent to receive a mAB as part of routine care, should they desire mAB treatment. Patients are told which mAB they are receiving, and physicians and patients can agree to the assigned mAB or request a specific mAB. It is the treating physicians' and patients' choice to accept the assigned mAB or not. The QI committee considered these steps to represent adequate consent to participate. The IRB considered that the provision of mAB therapy therefore fell under quality improvement and only the additional data collection and analyses represented research. The IRB waived any additional consent requirements.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lilly Bamlanivimab | Experimental | The Lilly monoclonal antibody bamlanivimab will be administered according to FDA EUA guidelines. Dosing is 700 mg intravenously times one within 10 days of COVID-19 symptom onset. |
|
| Regeneron Casirivimab + Imdevimab | Experimental | The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset. |
|
| Lilly Bamlanivimab + Etesevimab | Experimental | The Lilly monoclonal antibody cocktail of bamlanivimab + etesevimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset. |
|
| Sotrovimab | Experimental | The monoclonal antibody of sotrovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset. |
|
| Bebtelovimab | Experimental |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lilly Bamlanivimab | Biological | Administration of Lilly Bamlanivimab to COVID positive patients |
|
| Measure | Description | Time Frame |
|---|---|---|
| Hospital-free Days | Days alive and free from hospitalization. Patients that are both living and not in the hospital will meet criteria to be counted in this outcome. Deaths were rare and therefore the upper and lower end of the IQR are both 28, in addition to the median. This outcome measure does reflect median hospital free days and interquartile ranges for all groups. | 28 days after initial participation |
| Measure | Description | Time Frame |
|---|---|---|
| All-cause Mortality at 28 Days | All-cause mortality at 28 days. | 28 days after initial participation |
| SARS-CoV-2 Nasopharyngeal Viral Loads | Where feasible SARS-CoV-2 nasopharyngeal viral loads among participants from baseline and longitudinally through day 28 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Erin McCreary, PharmD | University of Pittsburgh | Study Director |
| David T Huang, MD, MPH | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UPMC | Pittsburgh | Pennsylvania | 15213 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35834252 | Derived | Huang DT, McCreary EK, Bariola JR, Minnier TE, Wadas RJ, Shovel JA, Albin D, Marroquin OC, Kip KE, Collins K, Schmidhofer M, Wisniewski MK, Nace DA, Sullivan C, Axe M, Meyers R, Weissman A, Garrard W, Peck-Palmer OM, Wells A, Bart RD, Yang A, Berry LR, Berry S, Crawford AM, McGlothlin A, Khadem T, Linstrum K, Montgomery SK, Ricketts D, Kennedy JN, Pidro CJ, Nakayama A, Zapf RL, Kip PL, Haidar G, Snyder GM, McVerry BJ, Yealy DM, Angus DC, Seymour CW. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial. JAMA Netw Open. 2022 Jul 1;5(7):e2220957. doi: 10.1001/jamanetworkopen.2022.20957. | |
| 35713300 |
Not provided
Not provided
De-identified participant-level data underlying the results reported in journal articles, subject to appropriate security controls, may be available for sharing with other researchers.
Relevant data may be available 1 year following publication
Data access is subject to a methodologically sound proposal and the necessary data sharing agreements.
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Lilly Bamlanivimab | The Lilly monoclonal antibody bamlanivimab will be administered according to FDA EUA guidelines. Dosing is 700 mg intravenously times one within 10 days of COVID-19 symptom onset. Lilly Bamlanivimab: Administration of Lilly Bamlanivimab to COVID positive patients |
| FG001 | Regeneron Casirivimab + Imdevimab | The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset. Regeneron Casirivimab + Imdevimab: Administration of Regeneron Casirivimab + Imdevimab to COVID positive patients |
| FG002 | Lilly Bamlanivimab + Etesevimab | The Lilly monoclonal antibody cocktail of bamlanivimab + etesevimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset. Lilly Bamlanivimab + Etesevimab: Administration of Lilly Bamlanivimab + Etesevimab to COVID positive patients |
| FG003 | Sotrovimab | The monoclonal antibody of sotrovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset. Sotrovimab: Administration of Sotrovimab to COVID positive patients |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Lilly Bamlanivimab | The Lilly monoclonal antibody bamlanivimab will be administered according to FDA EUA guidelines. Dosing is 700 mg intravenously times one within 10 days of COVID-19 symptom onset. Lilly Bamlanivimab: Administration of Lilly Bamlanivimab to COVID positive patients |
| BG001 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Hospital-free Days | Days alive and free from hospitalization. Patients that are both living and not in the hospital will meet criteria to be counted in this outcome. Deaths were rare and therefore the upper and lower end of the IQR are both 28, in addition to the median. This outcome measure does reflect median hospital free days and interquartile ranges for all groups. | Every patient who received mAb treatment | Posted | Median | Inter-Quartile Range | days | 28 days after initial participation |
|
6 months
Adverse events were reported by treating clinicians at each treatment center in a secure, nonpunative, system safety database and adjudicated by study researchers
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Lilly Bamlanivimab | The Lilly monoclonal antibody bamlanivimab will be administered according to FDA EUA guidelines. Dosing is 700 mg intravenously times one within 10 days of COVID-19 symptom onset. Lilly Bamlanivimab: Administration of Lilly Bamlanivimab to COVID positive patients |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| chest pain | Cardiac disorders | Non-systematic Assessment | chest pain during infusion reaction |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| infusion reaction | Product Issues | Non-systematic Assessment |
Results are presented before any prespecified statistical trigger was reached. Lack of patient-level variant data limited ability to assess comparative effectiveness relative to variant strains. The EHR eligibility screen identified most, but not all, EUA risk factors and could not identify if a patient was asymptomatic or severely ill. Finally, vaccination status was unable to be ascertained for this cohort which may impact effectiveness of monoclonal antibody therapy.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Erin McCreary | UPMC | 4845159589 | mccrearye3@upmc.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan: Bam-etes vs bam | May 2, 2022 | Mar 14, 2023 | Prot_SAP_001.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan: cas-imd | Jul 26, 2021 | May 21, 2023 | SAP_002.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C000711488 | imdevimab |
| C000711968 | etesevimab |
| C000711967 | sotrovimab |
| C000716927 | bebtelovimab |
Not provided
Not provided
Not provided
The study is an adaptive platform and as such is intended to study multiple interventions simultaneously, does not have a defined sample size, and is intended to move forward in perpetual fashion with domains and interventions being added and subtracted over time. For example, interventions will be added and subtracted depending on federal decisions regarding monoclonal antibodies, such as granting or revoking authorization for use.
Not provided
Not provided
Not provided
Not provided
The monoclonal antibody of bebtelovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
|
| Regeneron Casirivimab + Imdevimab | Biological | Administration of Regeneron Casirivimab + Imdevimab to COVID positive patients |
|
| Lilly Bamlanivimab + Etesevimab | Biological | Administration of Lilly Bamlanivimab + Etesevimab to COVID positive patients |
|
| Sotrovimab | Biological | Administration of Sotrovimab to COVID positive patients |
|
| Bebtelovimab | Biological | Administration of Bebtelovimab to COVID positive patients |
|
| 28 days after initial participation |
| SARS-CoV-2 Plasma Viral Loads | Where feasible SARS-CoV-2 plasma viral loads among participants from baseline and longitudinally through day 28 | 28 days after initial participation |
| SARS-CoV-2 Antibody Titers | Where feasible SARS-CoV-2 antibody titers at baseline and longitudinally through day 28 | 28 days after initial participation |
| SARS-CoV-2 Antibody Neutralization | Where feasible SARS-CoV-2 antibody neutralization at baseline and longitudinally through day 28 | 28 days after initial participation |
| SARS-CoV-2 Immune Responses | Where feasible SARS-CoV-2 immune responses at baseline and longitudinally through day 28 | 28 days after initial participation |
| Detection of SARS-CoV-2 Variants Through Next-generation Sequencing | Where feasible detection of SARS-CoV-2 variants through next-generation sequencing at baseline and longitudinally through day 28 | 28 days after initial participation |
| Duration of SAR-CoV-2 Infectivity | Where feasible determining the duration of SAR-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding | 28 days after initial participation |
| Non-culture Surrogates for SARS-CoV-2 Infectivity | Where feasible determining non-culture surrogates for SARS-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding | 28 days after initial participation |
| Non-culture Surrogates for SARS-CoV-2 Infectivity | Where feasible determining non-culture surrogates for SARS-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding | 90 days after initial participation |
| Duration of SAR-CoV-2 Infectivity | Where feasible determining the duration of SAR-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding | 90 days after initial participation |
| ED Visit Within 28 Days | Duration of study |
| Derived |
| Hirsch C, Park YS, Piechotta V, Chai KL, Estcourt LJ, Monsef I, Salomon S, Wood EM, So-Osman C, McQuilten Z, Spinner CD, Malin JJ, Stegemann M, Skoetz N, Kreuzberger N. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2. |
| 35697146 | Derived | McCreary EK, Bariola JR, Minnier TE, Wadas RJ, Shovel JA, Albin D, Marroquin OC, Kip KE, Collins K, Schmidhofer M, Wisniewski MK, Nace DA, Sullivan C, Axe M, Meyers R, Weissman A, Garrard W, Peck-Palmer OM, Wells A, Bart RD, Yang A, Berry LR, Berry S, Crawford AM, McGlothlin A, Khadem T, Linstrum K, Montgomery SK, Ricketts D, Kennedy JN, Pidro CJ, Haidar G, Snyder GM, McVerry BJ, Yealy DM, Angus DC, Nakayama A, Zapf RL, Kip PL, Seymour CW, Huang DT. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial. Contemp Clin Trials. 2022 Aug;119:106822. doi: 10.1016/j.cct.2022.106822. Epub 2022 Jun 11. |
| 34473343 | Derived | Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. |
| 34034784 | Derived | Huang DT, McCreary EK, Bariola JR, Wadas RJ, Kip KE, Marroquin OC, Koscumb S, Collins K, Shovel JA, Schmidhofer M, Wisniewski MK, Sullivan C, Yealy DM, Axe M, Nace DA, Haidar G, Khadem T, Linstrum K, Snyder GM, Seymour CW, Montgomery SK, McVerry BJ, Berry L, Berry S, Meyers R, Weissman A, Peck-Palmer OM, Wells A, Bart R, Albin DL, Minnier T, Angus DC. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization. Trials. 2021 May 25;22(1):363. doi: 10.1186/s13063-021-05316-3. |
| Regeneron Casirivimab + Imdevimab |
The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset. Regeneron Casirivimab + Imdevimab: Administration of Regeneron Casirivimab + Imdevimab to COVID positive patients |
| BG002 | Lilly Bamlanivimab + Etesevimab | The Lilly monoclonal antibody cocktail of bamlanivimab + etesevimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset. Lilly Bamlanivimab + Etesevimab: Administration of Lilly Bamlanivimab + Etesevimab to COVID positive patients |
| BG003 | Sotrovimab | The monoclonal antibody of sotrovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset. Sotrovimab: Administration of Sotrovimab to COVID positive patients |
| BG004 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| OG001 |
| Regeneron Casirivimab + Imdevimab |
The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset. Regeneron Casirivimab + Imdevimab: Administration of Regeneron Casirivimab + Imdevimab to COVID positive patients |
| OG002 | Lilly Bamlanivimab + Etesevimab | The Lilly monoclonal antibody cocktail of bamlanivimab + etesevimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset. Lilly Bamlanivimab + Etesevimab: Administration of Lilly Bamlanivimab + Etesevimab to COVID positive patients |
| OG003 | Sotrovimab | The monoclonal antibody of sotrovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset. Sotrovimab: Administration of Sotrovimab to COVID positive patients |
|
|
|
| Secondary | All-cause Mortality at 28 Days | All-cause mortality at 28 days. | Posted | Count of Participants | Participants | 28 days after initial participation |
|
|
|
| Secondary | SARS-CoV-2 Nasopharyngeal Viral Loads | Where feasible SARS-CoV-2 nasopharyngeal viral loads among participants from baseline and longitudinally through day 28 | Participants were not consented for samples due to limited trial resources, data not collected | Posted | 28 days after initial participation |
|
|
| Secondary | SARS-CoV-2 Plasma Viral Loads | Where feasible SARS-CoV-2 plasma viral loads among participants from baseline and longitudinally through day 28 | Participants were not consented for samples due to limited trial resources, data not collected | Posted | 28 days after initial participation |
|
|
| Secondary | SARS-CoV-2 Antibody Titers | Where feasible SARS-CoV-2 antibody titers at baseline and longitudinally through day 28 | Participants were not consented for samples due to limited trial resources, data not collected | Posted | 28 days after initial participation |
|
|
| Secondary | SARS-CoV-2 Antibody Neutralization | Where feasible SARS-CoV-2 antibody neutralization at baseline and longitudinally through day 28 | Participants were not consented for samples due to limited trial resources, data not collected | Posted | 28 days after initial participation |
|
|
| Secondary | SARS-CoV-2 Immune Responses | Where feasible SARS-CoV-2 immune responses at baseline and longitudinally through day 28 | Participants were not consented for samples due to limited trial resources, data not collected | Posted | 28 days after initial participation |
|
|
| Secondary | Detection of SARS-CoV-2 Variants Through Next-generation Sequencing | Where feasible detection of SARS-CoV-2 variants through next-generation sequencing at baseline and longitudinally through day 28 | Participants were not consented for samples due to limited trial resources, data not collected | Posted | 28 days after initial participation |
|
|
| Secondary | Duration of SAR-CoV-2 Infectivity | Where feasible determining the duration of SAR-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding | Participants were not consented for samples due to limited trial resources, data not collected | Posted | 28 days after initial participation |
|
|
| Secondary | Non-culture Surrogates for SARS-CoV-2 Infectivity | Where feasible determining non-culture surrogates for SARS-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding | Participants were not consented for samples due to limited trial resources, data not collected | Posted | 28 days after initial participation |
|
|
| Secondary | Non-culture Surrogates for SARS-CoV-2 Infectivity | Where feasible determining non-culture surrogates for SARS-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding | Participants were not consented for samples due to limited trial resources, data not collected | Posted | 90 days after initial participation |
|
|
| Secondary | Duration of SAR-CoV-2 Infectivity | Where feasible determining the duration of SAR-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding | Analysis not feasible due to limitations of pandemic, Participants were not consented for samples due to limited trial resources, data not collected | Posted | 90 days after initial participation |
|
|
| Secondary | ED Visit Within 28 Days | Not feasible due to nature of data and treatment sites during pandemic, data not collected | Posted | Duration of study |
|
|
| 1 |
| 128 |
| 0 |
| 128 |
| 0 |
| 128 |
| EG001 | Regeneron Casirivimab + Imdevimab | The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset. Regeneron Casirivimab + Imdevimab: Administration of Regeneron Casirivimab + Imdevimab to COVID positive patients | 12 | 2,454 | 7 | 2,454 | 17 | 2,454 |
| EG002 | Lilly Bamlanivimab + Etesevimab | The Lilly monoclonal antibody cocktail of bamlanivimab + etesevimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset. Lilly Bamlanivimab + Etesevimab: Administration of Lilly Bamlanivimab + Etesevimab to COVID positive patients | 7 | 885 | 0 | 885 | 12 | 885 |
| EG003 | Sotrovimab | The monoclonal antibody of sotrovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset. Sotrovimab: Administration of Sotrovimab to COVID positive patients | 7 | 1,104 | 4 | 1,104 | 6 | 1,104 |
|
| other infusion reaction | Product Issues | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |